147 related articles for article (PubMed ID: 29783765)
21. Novel lead structures for p38 MAP kinase via FieldScreen virtual screening.
Cheeseright TJ; Holm M; Lehmann F; Luik S; Göttert M; Melville JL; Laufer S
J Med Chem; 2009 Jul; 52(14):4200-9. PubMed ID: 19489590
[TBL] [Abstract][Full Text] [Related]
22. 2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics.
Zeng Q; Bourbeau MP; Wohlhieter GE; Yao G; Monenschein H; Rider JT; Lee MR; Zhang S; Lofgren J; Freeman D; Li C; Tominey E; Huang X; Hoffman D; Yamane H; Tasker AS; Dominguez C; Viswanadhan VN; Hungate R; Zhang X
Bioorg Med Chem Lett; 2010 Mar; 20(5):1652-6. PubMed ID: 20137932
[TBL] [Abstract][Full Text] [Related]
23. Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives.
Castro A; Encinas A; Gil C; Bräse S; Porcal W; Pérez C; Moreno FJ; Martínez A
Bioorg Med Chem; 2008 Jan; 16(1):495-510. PubMed ID: 17919914
[TBL] [Abstract][Full Text] [Related]
24. Effects of Single-Nucleotide Polymorphisms in Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2): A Comprehensive Study.
Khalid Z; Almaghrabi O
Comput Math Methods Med; 2020; 2020():7419512. PubMed ID: 33082841
[TBL] [Abstract][Full Text] [Related]
25. Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.
Dorsch D; Schadt O; Stieber F; Meyring M; Grädler U; Bladt F; Friese-Hamim M; Knühl C; Pehl U; Blaukat A
Bioorg Med Chem Lett; 2015 Apr; 25(7):1597-602. PubMed ID: 25736998
[TBL] [Abstract][Full Text] [Related]
26. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.
Michalczyk A; Klüter S; Rode HB; Simard JR; Grütter C; Rabiller M; Rauh D
Bioorg Med Chem; 2008 Apr; 16(7):3482-8. PubMed ID: 18316192
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
Zhang P; Hu HR; Bian SH; Huang ZH; Chu Y; Ye DY
Eur J Med Chem; 2013 Mar; 61():95-103. PubMed ID: 23047001
[TBL] [Abstract][Full Text] [Related]
28. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors.
Converso A; Hartingh T; Garbaccio RM; Tasber E; Rickert K; Fraley ME; Yan Y; Kreatsoulas C; Stirdivant S; Drakas B; Walsh ES; Hamilton K; Buser CA; Mao X; Abrams MT; Beck SC; Tao W; Lobell R; Sepp-Lorenzino L; Zugay-Murphy J; Sardana V; Munshi SK; Jezequel-Sur SM; Zuck PD; Hartman GD
Bioorg Med Chem Lett; 2009 Feb; 19(4):1240-4. PubMed ID: 19155174
[TBL] [Abstract][Full Text] [Related]
29. Research Resource: Roles for Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CaMKK2) in Systems Metabolism.
Marcelo KL; Ribar T; Means CR; Tsimelzon A; Stevens RD; Ilkayeva O; Bain JR; Hilsenbeck SG; Newgard CB; Means AR; York B
Mol Endocrinol; 2016 May; 30(5):557-72. PubMed ID: 27003444
[TBL] [Abstract][Full Text] [Related]
30. 14-3-3 protein inhibits CaMKK1 by blocking the kinase active site with its last two C-terminal helices.
Petrvalska O; Honzejkova K; Koupilova N; Herman P; Obsilova V; Obsil T
Protein Sci; 2023 Nov; 32(11):e4805. PubMed ID: 37817008
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of CaMKK2 reverses age-associated decline in bone mass.
Pritchard ZJ; Cary RL; Yang C; Novack DV; Voor MJ; Sankar U
Bone; 2015 Jun; 75():120-7. PubMed ID: 25724145
[TBL] [Abstract][Full Text] [Related]
32. Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.
Charnley AK; Convery MA; Lakdawala Shah A; Jones E; Hardwicke P; Bridges A; Ouellette M; Totoritis R; Schwartz B; King BW; Wisnoski DD; Kang J; Eidam PM; Votta BJ; Gough PJ; Marquis RW; Bertin J; Casillas L
Bioorg Med Chem; 2015 Nov; 23(21):7000-6. PubMed ID: 26455654
[TBL] [Abstract][Full Text] [Related]
33. Kinase Crystal Miner: A Powerful Approach to Repurposing 3D Hinge Binding Fragments and Its Application to Finding Novel Bruton Tyrosine Kinase Inhibitors.
Mukherjee P; Bentzien J; Bosanac T; Mao W; Burke M; Muegge I
J Chem Inf Model; 2017 Sep; 57(9):2152-2160. PubMed ID: 28792217
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors.
Lü S; Luo Q; Hao X; Li X; Ji L; Zheng W; Wang F
Bioorg Med Chem Lett; 2011 Dec; 21(23):6964-8. PubMed ID: 22033461
[TBL] [Abstract][Full Text] [Related]
35. Explicit treatment of active-site waters enhances quantum mechanical/implicit solvent scoring: Inhibition of CDK2 by new pyrazolo[1,5-a]pyrimidines.
Hylsová M; Carbain B; Fanfrlík J; Musilová L; Haldar S; Köprülüoğlu C; Ajani H; Brahmkshatriya PS; Jorda R; Kryštof V; Hobza P; Echalier A; Paruch K; Lepšík M
Eur J Med Chem; 2017 Jan; 126():1118-1128. PubMed ID: 28039837
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological evaluation of tetrahydro[1,4]diazepino[1,2-a]indol-1-ones as cyclin-dependent kinase inhibitors.
Putey A; Fournet G; Lozach O; Perrin L; Meijer L; Joseph B
Eur J Med Chem; 2014 Aug; 83():617-29. PubMed ID: 24998602
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological inhibition of CaMKK2 with the selective antagonist STO-609 regresses NAFLD.
York B; Li F; Lin F; Marcelo KL; Mao J; Dean A; Gonzales N; Gooden D; Maity S; Coarfa C; Putluri N; Means AR
Sci Rep; 2017 Sep; 7(1):11793. PubMed ID: 28924233
[TBL] [Abstract][Full Text] [Related]
38. Discovery of highly potent, selective, covalent inhibitors of JAK3.
Kempson J; Ovalle D; Guo J; Wrobleski ST; Lin S; Spergel SH; Duan JJ; Jiang B; Lu Z; Das J; Yang BV; Hynes J; Wu H; Tokarski J; Sack JS; Khan J; Schieven G; Blatt Y; Chaudhry C; Salter-Cid LM; Fura A; Barrish JC; Carter PH; Pitts WJ
Bioorg Med Chem Lett; 2017 Oct; 27(20):4622-4625. PubMed ID: 28927786
[TBL] [Abstract][Full Text] [Related]
39. Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.
Akué-Gédu R; Rossignol E; Azzaro S; Knapp S; Filippakopoulos P; Bullock AN; Bain J; Cohen P; Prudhomme M; Anizon F; Moreau P
J Med Chem; 2009 Oct; 52(20):6369-81. PubMed ID: 19788246
[TBL] [Abstract][Full Text] [Related]
40. Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B.
Collins I; Caldwell J; Fonseca T; Donald A; Bavetsias V; Hunter LJ; Garrett MD; Rowlands MG; Aherne GW; Davies TG; Berdini V; Woodhead SJ; Davis D; Seavers LC; Wyatt PG; Workman P; McDonald E
Bioorg Med Chem; 2006 Feb; 14(4):1255-73. PubMed ID: 16249095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
